Propagation of Human Prostate Cancer Stem-Like Cells Occurs through EGFR-Mediated ERK Activation

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Rybak, Adrian P ^a,b,c   Ingram, Alistair J ^a,b,c   Tang, Damu ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1;

ARTICLE; CANCER STEM CELL; CELL RENEWAL; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGENS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR;

EID: 84876422491     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061716     Document Type: Article

References (54)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Williams H, Powell IJ, (2009) Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol 472: 439-453.
3. Ross JS, (2007) The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test. Adv Anat Pathol 14: 353-357.
4. Moon C, Park JC, Chae YK, Yun JH, Kim S, (2008) Current status of experimental therapeutics for prostate cancer. Cancer Lett 266: 116-134.
5. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, et al. (2007) Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 46: 1-14.
6. Lawson DA, Witte ON, (2007) Stem cells in prostate cancer initiation and progression. J Clin Invest 117: 2044-2050.
7. Kasper S, (2008) Stem cells: The root of prostate cancer? J Cell Physiol 216: 332-336.
8. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
9. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511.
10. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
11. Rybak AP, He L, Kapoor A, Cutz JC, Tang D, (2011) Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim Biophys Acta 1813: 683-694.
12. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, et al. (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 106: 268-273.
13. Miki J, Furusato B, Li H, Gu Y, Takahashi H, et al. (2007) Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-3161.
14. Li H, Zhou J, Miki J, Furusato B, Gu Y, et al. (2008) Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells. Exp Cell Res 314: 92-102.
15. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI, (2011) Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun 2: 162.
16. Yamamoto H, Masters JR, Dasgupta P, Chandra A, Popert R, et al. (2012) CD49f Is an Efficient Marker of Monolayer- and Spheroid Colony-Forming Cells of the Benign and Malignant Human Prostate. PLoS One 7: e46979.
17. Salvatori L, Caporuscio F, Verdina A, Starace G, Crispi S, et al. (2012) Cell-to-cell signaling influences the fate of prostate cancer stem cells and their potential to generate more aggressive tumors. PLoS One 7: e31467.
18. Li Y, Wu D, Chen B, Ingram A, He L, et al. (2004) ATM activity contributes to the tumor-suppressing functions of p14ARF. Oncogene 23: 7355-7365.
19. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, et al. (2004) Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 104: 3712-3721.
20. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471.
21. Kelly JJ, Stechishin O, Chojnacki A, Lun X, Sun B, et al. (2009) Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells 27: 1722-1733.
22. Rojas M, Yao S, Lin YZ, (1996) Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 271: 27456-27461.
23. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, et al. (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9: 2313-2320.
24. Gan HK, Walker F, Burgess AW, Rigopoulos A, Scott AM, et al. (2007) The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J Biol Chem 282: 2840-2850.
25. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, et al. (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A 95: 12022-12027.
26. Honegger AM, Dull TJ, Felder S, Van Obberghen E, Bellot F, et al. (1987) Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51: 199-209.
27. Colburn NH, Bruegge WF, Bates JR, Gray RH, Rossen JD, et al. (1978) Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res 38: 624-634.
28. Shin SI, Freedman VH, Risser R, Pollack R, (1975) Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci U S A 72: 4435-4439.
29. Freedman VH, Shin SI, (1974) Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3: 355-359.
30. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, et al. (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279.
31. Quesnelle KM, Boehm AL, Grandis JR, (2007) STAT-mediated EGFR signaling in cancer. J Cell Biochem 102: 311-319.
32. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, et al. (1998) Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest 102: 1385-1392.
33. Kaptein A, Paillard V, Saunders M, (1996) Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem 271: 5961-5964.
34. Ni Z, Lou W, Leman ES, Gao AC, (2000) Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 60: 1225-1228.
35. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, et al. (2002) Stat3 activation in prostatic carcinomas. Prostate 51: 241-246.
36. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632.
37. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, et al. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970.
38. Wei F, Xie Y, Tao L, Tang D, (2010) Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. Cell Signal 22: 1783-1789.
39. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
40. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, et al. (1984) Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755-7760.
41. Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, et al. (2000) Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82: 186-194.
42. Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, et al. (2008) Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 27: 3201-3210.
43. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, et al. (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19: 264-271.
44. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A, (2004) Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 14: 1086-1096.
45. Shah RB, Ghosh D, Elder JT, (2006) Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate 66: 1437-1444.
46. Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, et al. (2007) Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 13: 6579-6584.
47. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, et al. (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53: 3217-3220.
48. Mimeault M, Johansson SL, Batra SK, (2012) Pathobiological implications of the expression of EGFR, pAkt, NF-kappaB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One 7: e31919.
49. Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, et al. (2008) Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem 283: 10958-10966.
50. Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, et al. (2010) Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 70: 7500-7513.
51. Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, et al. (2010) Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 28: 1930-1939.
52. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, et al. (2011) EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 19: 86-100.
53. Hong SK, Kim JH, Lin MF, Park JI, (2011) The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. Exp Cell Res 317: 2671-2682.
54. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ, (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284.